Lupin is finally set to launch its inhalation drug Albuterol after it received the US FDA nod for the product. Lupin had filed the application for the drug in 2017, and started manufacturing the product in July. However, the Street is looking for a quick-ramp up of sales in the US, and a follow-up with other launches. The stock has been flat in trade on Wednesday.
While the product is expected to improve US revenues substantially in the coming years, Lupin’s US revenues had hit a rough patch in the first quarter, which dented the enthusiasm for its stock lately. But with this launch, the Street is factoring in a significant upside in earnings over the next two years. Any set back in the earnings growth could hamper its stock price.
The launch is expected to add about $80-90 million in sales in the coming year, say analysts. The drug Albuterol currently accounts for about $1 billion in sales in the US. Lupin is expected to garner a decent share of the market.
This launch will help boost its US revenues, which has seen a sharp decline in the last quarter. Seasonally lower sales of generic Tamiflu and the recall of metformin dealt a heavy blow to Lupin’s US sales in the last quarter which contracted 25% quarter-on-quarter in Q1.